
usd pm et
summari global medic devic manufactur oper segment cardiac vascular
minim invas therapi restor therapi diabet
price-to-earnings oper ep
risk assess reflect exposur intens
competit area medic equip market
typic character short product life cycl
price pressur threat new market entrant
howev think potenti neg off-set
mani competit advantag scale
oper sale forc product breadth
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain buy
rais target
base multipl
ep multipl
three-year rang reflect
launch grow exposur robot
oct-q ep vs surpass
estim lift fy apr ep
fy ep
sale grew yoy organ
expect led emerg
market growth organ basi
cardiac vascular group grew
restor therapi group grew
acceler fiscal fy
gross margin yoy primarili due
unfavor foreign exchang impact
basi point bp partial due china
strong improv sg /kevin huang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
global oper
corpor overview lead manufactur develop market medic
devic therapi compani report total net sale fiscal year apr billion
broken follow oper segment cardiac vascular group billion
minim invas technolog group billion restor therapi group billion
cardiac vascular group compris cardiac rhythm heart failur crhf diseas
manag divis coronari structur heart divis aortic peripher venou divis
chrf divis develop manufactur market product diagnosi treatment
manag heart rhythm disord heart failur princip product servic offer
implant cardiac resynchron therapi devic atrial fibril ablat product
coronari structur heart divis includ therapi treat coronari arteri diseas heart valv
disord product coronari stent replac heart valv aortic peripher
venou divis compris comprehens line product therapi treat aortic diseas
includ product endovascular stent graft system peripher drug coat balloon
well peripher vascular diseas venou diseas
minim invas therapi group consist surgic innov divis
market advanc gener surgic product includ surgic stapl devic vessel seal
instrument wound closur electrosurgeri product hernia mechan devic mesh implant well
gynecolog product therapi treat diseas condit typic exclus
address surgeon respiratori gastrointestin renal divis develop manufactur
market product emerg field minim invas gastrointestin diagnost therapi
respiratori monitor airway manag ventil therapi treatment renal
restor therapi group made spine brain therapi specialti therapi pain
therapi divis spine divis develop manufactur market comprehens line
medic devic implant use treatment spine musculoskelet system includ
biolog solut orthoped dental market brain therapi divis develop manufactur
market integr portfolio devic therapi treatment neurolog disord
diseas well surgic technolog design improv precis workflow neuro
procedur specialti therapi divis develop manufactur market product therapi
treat diseas ear nose throat ent help control system overact bladder
non-obstruct urinari retent chronic fecal incontin pain therapi divis develop
manufactur market spinal cord stimul system implant drug infus system chronic
pain well intervent product
diabet group develop manufactur market product servic manag
type type ii diabet princip product servic offer group includ insulin pump
minim system continu glucos monitor system therapi manag
softwar help patient healthcar provid manag diabet treatment
competit landscap compet therapeut diagnost medic market
countri throughout world substanti exposur market us
fy revenu came non-u develop market came emerg market
one largest medic devic compani domin presenc mani
medic devic market high switch cost custom recent
environ manag care econom motiv custom consolid among health care
provid increas competit declin reimburs rate increasingli requir
compet basi price
robot compani develop robot guidanc system billion juli sold
patient deep vein thrombosi nutrit insuffici busi
billion mdt last major acquisit covidien plc januari billion januari
quarter achiev million synergi commit relat acquisit
financi trend revenu grew year-over-year billion fy april
compar five-year compound annual growth rate compound-annual-growth-rate adjust earn per share grew
year-over-year fy per share compar five-year compound-annual-growth-rate april
net debt total capit ratio cash flow oper billion
fy billion billion achiev fy fy respect
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d septemb
vs increas valu
 composit index
vs declin
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
plc rais target
ep multipl exce five-year rang
encourag pipelin newer product jan-q ep vs
higher estim maintain fy apr fy
ep estim jan-q sale increas includ million
neg impact foreign currenc constant currenc basi total revenu
grew year-over-year cardiac vascular group grew minim
invas therapi group grew restor therapi group grew
diabet group grew januari launch sale mazor
stealth divis robot guidanc platform expect key futur
growth driver neurosurgeri busi fy look forward launch
person close loop insulin pump system grant
breakthrough devic design fda today /kevin huang cfa
pm et cfra maintain sector
marketweight today first day annual jpmorgan
healthcar confer mani health care compani present
share drug maker alnylam pharmaceut neurocrin
bioscienc surg
intra-day manag care compani
also winner today increas share valu continu glucos
monitor cgm manufactur saw share rise
behemoth one large-cap health care
name today see plung share valu declin intra-day
weaker forward-look tone healthcar confer end januari
cfra expect see signific stock movement next
day compani continu provid updat outlook /kevin
analyst research note compani news
et cfra maintain buy opinion share medtron plc
rais target base multipl
ep multipl
three-year rang reflect compani numer upcom product launch
grow exposur robot oct-q ep vs surpass
estim lift fy apr ep fy
ep sale grew yoy organ
expect led emerg market growth organ basi
cardiac vascular group grew minim invas therapi group grew
restor therapi group grew diabet group grew
expect growth acceler fiscal fy launch
mani new product although gross margin yoy primarili due
unfavor foreign exchang impact basi point bp partial due
china tariff oper margin improv bp yoy strong improv
sg /kevin huang cfa
pm et cfra maintain buy opinion share medtron plc
lift target price base
multipl ep estim rais
valuat reflect increas confid futur robot offer
yesterday sep host investor day highlight
develop initi offer soft-tissu robot-assist surgeri ra
market long domin
target launch two year european launch slightli
year ra offer featur upgrad univers mean
suit multipl type surgeri includ open surgeri mobil
tower open-design surgeon consol hd visual mobil
modular robot arm given world-wide surgeri market estim
penetr ra solut think well-thought-out
offer long runway growth /kevin huang cfa
et cfra keep buy opinion share medtron plc
rais target base multipl
ep lift multipl reflect
promis upcom product launch grow exposur robot
jul-q ep vs beat estim rais fy
apr ep apr-q sale increas constant
currenc cc basi driven cc growth
emerg market cc basi cardiac vascular group grew
diabet group grew divis except
diabet group outperform expect diabet growth outsid
 grew strong clip busi declin mid-singl digit
competit challeng difficult comp month
host demonstr highli anticip in-develop gener surgeri
pm et cfra reiter buy opinion share medtron plc
lower target base multipl
ep multipl high-end
five-year rang encourag pipelin new
product apr-q ep vs beat estim lower
fy apr ep initi fy ep
apr-q sale increas organ basi driven
constant currenc cc growth emerg market cc
basi cardiac vascular group grew minim invas therapi
group grew restor therapi group grew diabet group
grew fy expect back half stronger headwind
anniversari numer product launch ramp continu anticip
fy launch surgic robot despit expect expenditur new
product launch believ achiev least basi point
cc oper margin expans fy /kevin huang cfa
pm et correct cfra maintain buy opinion share
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
